Renal dysfunction among HIV-infected patients starting antiretroviral therapy

被引:50
|
作者
Msango, Leonard [2 ,3 ]
Downs, Jennifer A. [1 ,3 ]
Kalluvya, Samuel E. [2 ,3 ]
Kidenya, Benson R. [2 ]
Kabangila, Rodrick [2 ,3 ]
Johnson, Warren D., Jr.
Fitzgerald, Daniel W.
Peck, Robert N. [2 ,3 ]
机构
[1] Weill Cornell Med Coll, Ctr Global Hlth, New York, NY 10065 USA
[2] Weill Bugando Univ Coll Hlth Sci, Mwanza, Tanzania
[3] Bugando Med Ctr, Mwanza, Tanzania
关键词
antiretroviral therapy; HIV; renal dysfunction; sub-Saharan Africa; RISK-FACTORS; SEROPOSITIVE PATIENTS; KIDNEY-DISEASE; SOUTH-AFRICA; ADULTS; TENOFOVIR; MORTALITY; ABNORMALITIES; PROTEINURIA; MANAGEMENT;
D O I
10.1097/QAD.0b013e328348a4b1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: HIV-related renal dysfunction is associated with high mortality. Data on the prevalence of renal dysfunction among HIV-infected outpatients starting antiretroviral therapy (ART) in sub-Saharan Africa are limited. Recent recommendations to include the nephrotoxic drug tenofovir in first-line ART regimens make clarification of this issue urgent. Methods: We screened for renal dysfunction by measuring serum creatinine, proteinuria, and microalbuminuria in HIV-positive outpatients initiating ART in Mwanza, Tanzania. We excluded patients with pre-existing renal disease, hypertension, diabetes, or hepatitis C virus co-infection. Estimated glomerular filtration rates (eGFRs) were calculated by Cockroft-Gault and Modification of Diet in Renal Disease equations. Results: Only 129 (36%) of 355 enrolled patients had normal eGFRs (grade 0 or 1) above 90 ml/min per 1.73 m(2). Grade 2 renal dysfunction (eGFR between 60 and 89 ml/min per 1.73 m(2)) was present in 137 patients (38.6%), and 87 patients (25%) had grade 3 dysfunction (eGFR between 30 and 59 ml/min per 1.73 m(2)). Microalbuminuria and proteinuria were detected in 72 and 36% of patients, respectively. Factors predictive of renal dysfunction in multivariate analysis included female sex [odds ratio (OR) 3.0, 95% confidence interval (1.8-5.1), P<0.0001], BMI less than 18.5 [OR 2.3 (1.3-4.1), P = 0.004], CD4(+) T-cell count below 200 cells/mu l [OR 2.3 (1.1-4.8), P = 0.04], and WHO clinical stage II or above [OR 1.6 (1.2-2.3), P = 0.001]. Conclusion: Renal dysfunction was highly prevalent in this population of HIV-positive outpatients initiating first ART in Tanzania. This highlights the critical and under-appreciated need to monitor renal function in HIV-positive patients in sub-Saharan Africa, particularly given the increasing use of tenofovir in first-line ART. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:1421 / 1425
页数:5
相关论文
共 50 条
  • [41] Nitric oxide levels in HIV-infected, untreated patients and HIV-infected patients receiving antiretroviral therapy
    Soccal, Renata Mezomo
    Mainardi de Carvalho, Jose Antonio
    Bochi, Guilherme Vargas
    Moresco, Rafael Noal
    Paz da Silva, Jose Edson
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2016, 79 : 302 - 307
  • [42] Staging for antiretroviral therapy among HIV-infected drug users
    Wood, E
    Hogg, RS
    Bonner, S
    Kerr, T
    Li, K
    Palepu, A
    Guillemi, S
    Schechter, MT
    Montaner, JSG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (10): : 1175 - 1177
  • [43] Hormonal contraception and antiretroviral therapy among HIV-infected women
    Amaral, Eliana
    Martino Viscola, Marco Aurelio
    Bahamondes, Luis
    [J]. REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2006, 28 (11): : 680 - 684
  • [44] Body weight evolution among HIV-infected patients starting antiretroviral therapy with dolutegravir or efavirenz based regimens in rural Tanzania
    Mapesi, H.
    Vanobberghen, F.
    Okuma, J.
    Eichenberger, A.
    Wilson, H. Ismael
    Ndege, R.
    Glass, T. Renee
    Paris, D. Henry
    Battegay, M.
    Weisser, M.
    Franzeck, F.
    Grp, K. I. U. L. A. R. C. O. Study
    [J]. HIV MEDICINE, 2021, 22 : 82 - 83
  • [45] GENDER EFFECT ON CHANGE OF BODY MASS INDEX AMONG ANTIRETROVIRAL-NAIVE HIV-INFECTED INDIVIDUALS STARTING ANTIRETROVIRAL THERAPY
    Nguyen, D. T.
    Chu, K.
    Dai, T.
    Easley, K.
    Nguyen, M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (02) : 711 - 711
  • [46] Antiretroviral therapy in HIV-infected children
    Fan, Conghai
    Zhang, Fengchao
    Chen, Chao
    [J]. MINERVA PEDIATRICA, 2019, 71 (05) : 455 - 460
  • [47] Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population
    Jensen-Fangel, S
    Pedersen, L
    Pedersen, C
    Larsen, CS
    Tauris, P
    Moller, A
    Sorensen, HT
    Obel, N
    [J]. AIDS, 2004, 18 (01) : 89 - 97
  • [48] Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Côté, HCF
    Magil, AB
    Harris, M
    Scarth, BJ
    Gadawski, I
    Wang, N
    Yu, E
    Yip, B
    Zalunardo, N
    Werb, R
    Hogg, R
    Harrigan, PR
    Montaner, JS
    [J]. ANTIVIRAL THERAPY, 2006, 11 (01) : 79 - 86
  • [49] CLINICALLY SIGNIFICANT DRUG INTERACTIONS AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
    So-Ngern, Apichot
    Montakantikul, Preecha
    Manosuthi, Weerawat
    [J]. SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2014, 45 (05) : 1023 - 1031
  • [50] Thromboses among HIV-Infected Patients during the Highly Active Antiretroviral Therapy Era
    Crum-Cianflone, Nancy F.
    Weekes, Jhamillia
    Bavaro, Mary
    [J]. AIDS PATIENT CARE AND STDS, 2008, 22 (10) : 771 - 778